Silence Therapeutics plc (SLN)Healthcare | Biotechnology | London, United Kingdom | NasdaqGM
9.29 USD
+0.20
(2.200%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:54 a.m. EDT
The investment case here is fundamentally broken despite the recent price bounce. While the company boasts a pristine balance sheet with negligible debt and massive cash reserves relative to obligations, the business itself is hemorrhaging cash with operating burn rates in the tens of millions and negative returns on equity. The market has already priced in this reality, driving the stock down nearly 76% over the last four years. The recent price action, which spiked above $10 before retreating, appears to be a speculative trap fueled by a single analyst's overly optimistic target price ($75) that ignores the lack of commercialized products or revenue traction. Crucially, insider activity shows a major shareholder trimming their stake, signaling a lack of confidence at the highest level. Options flow confirms this fear, with traders aggressively buying cheap put insurance while avoiding calls entirely. This is a classic 'value trap' where the clean balance sheet masks a deteriorating operational engine. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.201032 |
| AutoETS | 0.201034 |
| MSTL | 0.201142 |
| AutoTheta | 0.217909 |
| MSTL_70 | 0.230954 |
| MSTL_90 | 0.326762 |
| MSTL_70_90 | 0.362588 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 4.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.014 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.275 |
| Revenue per Share | 0.018 |
| Market Cap | 438,809,536 |
| Forward P/E | -23.82 |
| Beta | 1.38 |
| Website | https://www.silence-therapeutics.com |
As of July 11, 2026, 2:54 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $2.50, $5.00, $7.50) compared to negligible call volume. Implied volatility is significantly elevated for deep puts (36.75% vs ~2% for calls), indicating a market consensus expecting a sharp drop rather than a rally. The lack of significant call open interest suggests no organized bullish defense.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.43143296 |
| Address1 | 12 Hammersmith Grove |
| All Time High | 35.0 |
| All Time Low | 1.97 |
| Ask | 11.43 |
| Ask Size | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 564,620 |
| Average Daily Volume3 Month | 388,801 |
| Average Volume | 388,801 |
| Average Volume10Days | 564,620 |
| Beta | 1.38 |
| Bid | 6.64 |
| Bid Size | 2 |
| Book Value | 1.046 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.29 |
| Current Ratio | 9.833 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.41 |
| Day Low | 8.91 |
| Debt To Equity | 0.275 |
| Display Name | Silence Therapeutics |
| Earnings Call Timestamp End | 1,740,661,200 |
| Earnings Call Timestamp Start | 1,740,661,200 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -71,083,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.189 |
| Enterprise To Revenue | 439.644 |
| Enterprise Value | 368,861,376 |
| Eps Current Year | -0.4 |
| Eps Forward | -0.39 |
| Eps Trailing Twelve Months | -1.62 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.5894 |
| Fifty Day Average Change | 1.7006001 |
| Fifty Day Average Change Percent | 0.2240757 |
| Fifty Two Week Change Percent | 43.143295 |
| Fifty Two Week High | 11.06 |
| Fifty Two Week High Change | -1.7700005 |
| Fifty Two Week High Change Percent | -0.1600362 |
| Fifty Two Week Low | 4.19 |
| Fifty Two Week Low Change | 5.1 |
| Fifty Two Week Low Change Percent | 1.2171837 |
| Fifty Two Week Range | 4.19 - 11.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,599,571,800,000 |
| Float Shares | 27,460,873 |
| Forward Eps | -0.39 |
| Forward P E | -23.820513 |
| Free Cashflow | -45,655,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 88 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.79499 |
| Gross Profits | 667,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21767001 |
| Held Percent Institutions | 0.44566002 |
| Implied Shares Outstanding | 47,234,613 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. |
| Long Name | Silence Therapeutics plc |
| Market | us_market |
| Market Cap | 438,809,536 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_183280 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -75,039,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 212,555,760 |
| Number Of Analyst Opinions | 6 |
| Open | 9.03 |
| Operating Cashflow | -65,565,000 |
| Operating Margins | -35.65403 |
| Payout Ratio | 0.0 |
| Phone | 44 20 3457 6900 |
| Pre Market Change | -0.15999985 |
| Pre Market Change Percent | -1.7222804 |
| Pre Market Price | 9.13 |
| Pre Market Time | 1,784,029,404 |
| Previous Close | 9.09 |
| Price Eps Current Year | -23.225 |
| Price Hint | 2 |
| Price To Book | 8.8814535 |
| Price To Sales Trailing12 Months | 523.01495 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.824 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.71429 |
| Region | US |
| Regular Market Change | 0.2 |
| Regular Market Change Percent | 2.20022 |
| Regular Market Day High | 9.41 |
| Regular Market Day Low | 8.91 |
| Regular Market Day Range | 8.91 - 9.41 |
| Regular Market Open | 9.03 |
| Regular Market Previous Close | 9.09 |
| Regular Market Price | 9.29 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 233,638 |
| Return On Assets | -0.29794002 |
| Return On Equity | -0.92557997 |
| Revenue Growth | 1.972 |
| Revenue Per Share | 0.018 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 47,234,613 |
| Shares Percent Shares Out | 0.0367 |
| Shares Short | 1,733,018 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,057,236 |
| Short Name | Silence Therapeutics Plc - Amer |
| Short Percent Of Float | 0.048600003 |
| Short Ratio | 3.43 |
| Source Interval | 15 |
| Symbol | SLN |
| Target High Price | 75.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 29.16667 |
| Target Median Price | 25.0 |
| Total Cash | 70,078,000 |
| Total Cash Per Share | 1.484 |
| Total Debt | 136,000 |
| Total Revenue | 839,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.440525 |
| Two Hundred Day Average Change | 2.849475 |
| Two Hundred Day Average Change Percent | 0.44242898 |
| Type Disp | Equity |
| Volume | 233,638 |
| Website | https://www.silence-therapeutics.com |
| Zip | W6 7AP |